As­traZeneca keeps the ball rolling on Dai­ichi-part­nered En­her­tu, pick­ing up 2nd in­di­ca­tion in gas­tric can­cer

As­traZeneca’s big gam­ble on Dai­ichi Sankyo’s an­ti­body-drug con­ju­gate En­her­tu has al­ready paid off with a big ap­proval in breast can­cer more than a year ago. But the part­ners have big plans for their block­buster in the mak­ing, and a new nod in gas­tric can­cer will raise their spir­its even high­er.

The FDA on Fri­day ap­proved En­her­tu to treat lo­cal­ly ad­vanced or metasta­t­ic HER2-pos­i­tive gas­tric or gas­troe­sophageal junc­tion ade­no­car­ci­no­ma in pa­tients who have pre­vi­ous­ly un­der­gone at least one round of treat­ment with a Her­ceptin-based reg­i­men, As­traZeneca said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.